Abstract:
Platelets are increasingly recognized for their role as mediators of immune response and inflammation. As major components of the hematological system, they form an important bridge between immunity and coagulation. When platelets become hyperactivated in response to an infection, patients can develop immuno-thrombosis and coagulopathy. These derangements of hemostasis are particularly relevant in the context of infection with the novel coronavirus, SARS-CoV-2, and the subsequent development of coronavirus disease, COVID-19, a disease in which thromboembolic events are an important cause of morbidity and mortality.
